Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05681156 · ClinicalTrials.gov registry record
Curian S. Pneumo/Legionella Assay Beta Clinical Trial Protocol
A clinical trial, sponsored by Meridian Bioscience.
- Completed
- Registry status
- 199
- Enrollment target
NCT05681156: Completed study, sponsored by Meridian Bioscience.
NCT05681156 is a clinical trial that has completed, run by Meridian Bioscience. The registered enrollment target is 199 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05681156 has completed, sponsored by Meridian Bioscience.
- COMPLETED
- Registry status
- 199 participants
- Enrollment target
Study Summary
Beta trial to evaluate the preliminary clinical performance of the Curian S. pneumo/Legionella assay for its use in the qualitative detection of Streptococcus pneumoniae and/or Legionella pneumophila serogroup 1 antigens in human urine specimens.
Primary Outcome
Curian S. pneumo/Legionella Assay will be compared to the comparator assays (both FDA cleared)
Interventions
- OTHER N/A- There is no intervention.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2023-02-01 |
| Est. Completion | 2023-09-08 |
What the finished NCT05681156 record still lists
NCT05681156 is an observational study that tracks outcomes without assigning an intervention. The registered 199 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which N/A- There is no intervention. is the first listed.
NCT05681156 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05681156 about?
NCT05681156 is a clinical study titled "Curian S. Pneumo/Legionella Assay Beta Clinical Trial Protocol". Beta trial to evaluate the preliminary clinical performance of the Curian S. pneumo/Legionella assay for its use in the qualitative detection of Streptococcus pneumoniae and/or Legionella pneumophila serogroup 1 antigens in human urine specimens.
What is the current status of trial NCT05681156?
This trial is currently completed. The enrollment target is 199 participants. The study started on 2023-02-01. Estimated completion is 2023-09-08.
What interventions are being tested in trial NCT05681156?
The interventions under investigation include: N/A- There is no intervention. (OTHER).
Who is sponsoring clinical trial NCT05681156?
This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04312126 · 199 participants
The Beneficial Effects of Naps on Motor Learning
- NCT04951622 · 199 participants · Phase 3
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- NCT06474533 · 199 participants
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI